The logo of Swiss-based mail-order pharmacy and medical supplier Zur Rose Group is seen at the company's headquarters in Frauenfeld, Switzerland May 9, 2017. REUTERS/Arnd Wiegmann Stock Photo - Alamy
Zur Rose | LinkedIn
Zur Rose Group company information, funding & investors | Dealroom.co
Mega pharmacy “Zur Rose” takes over TeleClinic and fetches another 213 million CHF while APORA announces its start one month ago! | by Falk Altenhöfer | Medium
Zur Rose reopens European equity-linked bond market
Zur Rose Group AG
Gleiss Lutz advises Zur Rose Group on the establishment of the Doc Morris Adipositas Care portal | Gleiss Lutz
Zur Rose Group - Wikipedia
Zur Rose Group AG acquires PromoFarma.com - 2018-08-02 - Crunchbase Acquisition Profile
ACXIT Capital Partners advised Zur Rose Group on the successful placement of CHF 175M Convertible Bonds - ACXIT Capital Partners
Healthcare platform partnership in Switzerland
Zur Rose Group company information, funding & investors | Dealroom.co
Zur Rose Group - Wikitia
Zur Rose Group (SWX:ROSE) - Share price, News & Analysis - Simply Wall St
Zur Rose Group AG - Crunchbase Company Profile & Funding
Zur Rose Group AG
ZUR ROSE GROUP AG : 0RRB Stock Price | CH0042615283 | MarketScreener
Zur Rose Group AG acquires DocMorris - 2012-10-25 - Crunchbase Acquisition Profile
Zur Rose Group | LinkedIn
ZUR ROSE GROUP AG : ROSE Stock Price | CH0042615283 | MarketScreener
Is Zur Rose Group (VTX:ROSE) A Risky Investment?
Frauenfeld, Switzerland. 08th Apr, 2019. The headquarters of the Swiss Zur Rose Group in Frauenfeld, which owns the largest mail-order pharmacy in Europe, DocMorris. (for dpa: "DocMorris scares the industry with a
Zur Rose Group AG - price - share - stock-market
Zur Rose Group | LinkedIn
ROSE Institutional Ownership - Zur Rose Group AG (SIX) Stock
The logo of Swiss-based mail-order pharmacy and medical supplier Zur Rose Group is seen at the company's headquarters in Frauenfeld, Switzerland May 9, 2017. REUTERS/Arnd Wiegmann Stock Photo - Alamy
Acquisitions by Zur Rose Group | Tracxn
Business Performance - Annual Report 2019 | Zur Rose Group AG
Zur Rose AG (ISIN: CH0042615283) – Loss making failed IPO or long term growth opportunity ? | value and opportunity
Zur Rose Group AG - Crunchbase Company Profile & Funding
